Abstract

The present invention provides recombinant herpes virus of turkeys (HVT) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/20 - Antivirals for DNA viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention provides recombinant Newcastle disease virus (NDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an avian.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses

Abstract

The present invention provides recombinant canine distemper virus (CDV) viral vectors comprising a heterologous polynucleotide encoding an avian influenza antigen. The recombinant viral vectors are suitable for use in immunogenic compositions and vaccines, and can provide protection against avian influenza and other pathogens when administered to an animal.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses

Abstract

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 31/14 - Antivirals for RNA viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof

Abstract

The present invention relates i.a. to an IBV (infectious bronchitis virus) encoding for a heterologous DMV S (spike) protein or fragment thereof. Further, the present invention relates to an immunogenic composition comprising said IBV encoding for a heterologous DMV S (spike) protein or fragment thereof. Furthermore, the present invention relates to methods for immunizing a subject comprising administering to such subject the immunogenic composition of the present invention. Moreover, the present invention relates to methods of treating or preventing clinical signs caused by IBV in a subject of need, the method comprising administering to the subject a therapeutically effective amount of an immunogenic composition according to the present invention.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses

Goods & Services

Veterinary preparations for pets for the treatment of hypertension; veterinary preparations for pets for the treatment of chronic kidney disease; veterinary preparations for pets for the treatment of diseases and disorders of the alimentary tract and metabolism; veterinary preparations for the treatment of diseases and disorders of the cardiovascular system.

Goods & Services

Interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets. Providing medical and scientific research information in the field of parasites in pets. Veterinary services provided via mobile application software in the field of parasites in pets.

Goods & Services

Veterinary preparations.

Goods & Services

Veterinary preparations.

Goods & Services

Veterinary preparations.

Goods & Services

Veterinary preparations.

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in a non-human mammal/non-human mammal patient excluding a feline, in particular a canine/canine patient.

IPC Classes  ?

• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure

Goods & Services

(1) Interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets providing medical and scientific research information in the field of parasites in pets (1) Providing medical and scientific research information in the field of parasites in pets (2) Veterinary services provided via mobile application software in the field of parasites in pet animals

Goods & Services

(1) Interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets providing medical and scientific research information in the field of parasites in pets (1) Providing medical and scientific research information in the field of parasites in pets (2) Veterinary services provided via mobile application software in the field of parasites in pet animals

Goods & Services

(1) Veterinary vaccines

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more renal diseases and/or hypertension in a non-human mammal / non-human mammal patient, such as a dog or a cat.

IPC Classes  ?

• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with pimobendan and/or telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more cardiac diseases in a non-human mammal/non-human mammal patient, such as a dog or a cat.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more renal diseases and/or hypertension in a non-human mammal/non-human mammal patient, such as a dog or a cat.

IPC Classes  ?

• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 9/12 - Antihypertensives
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof in combination with pimobendan and/or telmisartan or pharmaceutically acceptable forms thereof, in particular for the prophylaxis and/or treatment of one or more cardiac diseases in a non-human mammal / non-human mammal patient, such as a dog or a cat.

IPC Classes  ?

• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Goods & Services

(1) Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders.

Goods & Services

(1) Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders.

Goods & Services

Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders

Goods & Services

Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders

Goods & Services

(1) Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders.

Goods & Services

(1) Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders.

Goods & Services

Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders

Goods & Services

Veterinary preparations, for the prevention and the treatment of metabolic diseases disorders; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damages and injuries; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; vaccines for veterinary use; sedatives for veterinary use; stem cells for veterinary use; surgical implants comprising living tissue and grown from stem cells for veterinary use; dietary and nutritional supplements for animals; dietetic animal foodstuffs for medical purposes; veterinary preparations, for the prevention and the treatment of endocrine disorders and diseases; veterinary preparations for the prevention and treatment of skin diseases; veterinary preparations, for the prevention and the treatment of oncological diseases; veterinary preparations, for the prevention and the treatment of gastrointestinal diseases; veterinary preparations for dental purposes; medicated mouth care preparations for animals; veterinary preparations, namely, anti-parasitic products for veterinary use; veterinary preparations for the prevention and treatment of ophthalmic diseases and disorders

Goods & Services

(1) Interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets. (1) Providing medical and scientific research information in the field of parasites in pets. (2) Veterinary services provided via mobile application software in the field of parasites in pets.

Goods & Services

Interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets. Providing medical and scientific research information in the field of parasites in pets. Veterinary services provided via mobile application software in the field of parasites in pets.

Abstract

The present invention relates to immunogenic compositions comprising (i) an antigen composition which comprises or consists of a virus antigen and (ii) a gel composition comprising a flavoring agent, wherein such immunogenic composition can be placed into the housing environment of livestock, in particular of pigs. Thereby the self-administration of the immunogenic composition by the pigs is enabled, which allows to simply induce an immune response in the animals, by a minimum workload for personnel and less stress for the pigs.

IPC Classes  ?

• A61P 31/20 - Antivirals for DNA viruses
• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A61K 39/12 - Viral antigens
• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23L 29/20 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention relates to methods for inducing an immune response in a subject, the method comprising administering orally to the subject an immunogenic composition comprising non-replicating virus antigen. In one example, an immunogenic composition is administered via the oral route to a pig, wherein the immunogenic composition comprises a recombinant virus capsid protein capable of forming a virus-like particle. This allows to simply induce an immune response in the pigs, while simultaneously reducing the propensity for adverse reactions, eliminating the risk of injection site reactions, avoiding pain, and putting less stress on the animals.

IPC Classes  ?

• A61P 31/20 - Antivirals for DNA viruses
• A23K 10/16 - Addition of microorganisms or extracts thereof, e.g. single-cell proteins, to feeding-stuff compositions
• A61K 39/12 - Viral antigens
• A23K 50/30 - Feeding-stuffs specially adapted for particular animals for swine
• A23L 29/20 - Foods or foodstuffs containing additivesPreparation or treatment thereof containing gelling or thickening agents
• C12N 15/866 - Baculoviral vectors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Goods & Services

(1) Aliments pour les animaux et additifs pour fourrages non à usage médical.

Abstract

The invention relates to crystalline complexes of velagliflozin and selected co-crystal forming agents, to methods for their preparation as well as to the use thereof for preparing medicaments.

IPC Classes  ?

• C07D 309/10 - Oxygen atoms
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61P 3/10 - Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

An optical system having a chamber for receiving an element of body fluid or tissue or environmental sample to be characterized has a light source for illuminating the chamber with light, and a spectrometer for recording a spectrum of light originating from the chamber. The light source has two separate LEDs to emit light having at least two spectral maxima of different wavelength ranges. The light from the light source is directed to the chamber. A method for determining a parameter representing a property of the element with the optical system, wherein, light having at least two spectral maxima of different wavelength ranges generated by separate LEDs is directed onto the element, a spectrum with reflected components of the light, scattered components of the light, and/or light caused by Raman scattering or fluorescence of the element is measured with the spectrometer, and the parameter is determined by evaluating the spectrum.

IPC Classes  ?

• G01N 21/25 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
• G01J 3/02 - SpectrometrySpectrophotometryMonochromatorsMeasuring colours Details
• G01J 3/44 - Raman spectrometryScattering spectrometry
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 21/33 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using ultraviolet light
• G01N 21/359 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry using infrared light using near infrared light
• G01N 33/487 - Physical analysis of biological material of liquid biological material

Abstract

The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulfoximine-pyridine derivatives of formulae (I), (Ia) or (Ib) The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulfoximine-pyridine derivatives of formulae (I), (Ia) or (Ib) The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulfoximine-pyridine derivatives of formulae (I), (Ia) or (Ib) wherein the variables are as defined in the description and/or in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in/on animals as well as crop protection agents.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• C07D 471/04 - Ortho-condensed systems

Abstract

A method for calibrating an optical system that has a chamber for receiving an element of body fluid or tissue or environmental sample uses a light source for illuminating the chamber with light, and a spectrometer for measuring a spectrum of light originating from the chamber, wherein the brightness of the light source is controlled while measuring a spectrum for calibration with the spectrometer so that the brightness of the light source is a reduced brightness, a brightness reduced relative to a nominal brightness of the light source, and/or a brightness reduced relative to a brightness of the light source when measuring the spectrum of the element; and/or wherein a spectrometer of the optical system is monitored with regard to a changed measurement behavior and upon detection of the changed measurement behavior of the spectrometer a calibration. Preferably spectra of preceding measurements are compared with each other.

IPC Classes  ?

• G01N 21/27 - ColourSpectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands using photo-electric detection
• G01N 21/31 - Investigating relative effect of material at wavelengths characteristic of specific elements or molecules, e.g. atomic absorption spectrometry
• G01N 21/65 - Raman scattering

Abstract

The present invention relates to N-oxide compounds of formula (I) or formula (Ia) or formula (Ib) The present invention relates to N-oxide compounds of formula (I) or formula (Ia) or formula (Ib) The present invention relates to N-oxide compounds of formula (I) or formula (Ia) or formula (Ib) wherein the variables are as defined in the description and/or in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in/on animals as well as crop protection agents.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A01N 43/90 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
• A01P 7/04 - Insecticides
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• C07D 471/04 - Ortho-condensed systems

Abstract

Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.

IPC Classes  ?

• A61M 5/315 - PistonsPiston-rodsGuiding, blocking or restricting the movement of the rodAppliances on the rod for facilitating dosing
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more renal diseases in a non-human mammal, such as a carnivore, in particular a cat or a dog.

IPC Classes  ?

• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

Systems and methods are described for treatment and/or prevention of a metabolic disorder and/or another medical condition in a patient (e.g., a feline) by administering to the patient a liquid pharmaceutical composition, preferably including one or more SGLT-2 inhibitor compound(s), via a delivery system that includes a syringe. The syringe includes features that facilitate easy, safe and effective doses of small volumetric amounts of the liquid pharmaceutical composition to the patient during administration.

IPC Classes  ?

• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61P 9/00 - Drugs for disorders of the cardiovascular system
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 38/00 - Medicinal preparations containing peptides
• A61P 3/00 - Drugs for disorders of the metabolism
• C07H 7/04 - Carbocyclic radicals
• A61P 1/18 - Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
• A61M 5/31 - Syringes Details
• C07H 15/203 - Monocyclic carbocyclic rings other than cyclohexane ringsBicyclic carbocyclic ring systems
• C07H 17/00 - Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
• C07H 17/02 - Heterocyclic radicals containing only nitrogen as ring hetero atoms
• C07H 19/01 - Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radicalNucleosidesMononucleotidesAnhydro derivatives thereof sharing oxygen

Abstract

The present invention relates to tetrazole substituted ethylsulfone/sulfoximine-pyridine derivatives of formula (I), (Ia) or (Ib) The present invention relates to tetrazole substituted ethylsulfone/sulfoximine-pyridine derivatives of formula (I), (Ia) or (Ib) wherein the variables are as defined in the description and/or in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in/on animals as well as as crop protection agents.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/4439 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
• A61K 31/444 - Non-condensed pyridinesHydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. amrinone
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 471/04 - Ortho-condensed systems

Goods & Services

(1) Veterinary preparations, namely, antiparasitic for ruminant.

Goods & Services

Veterinary preparations, namely, antiparasitic for ruminant

Abstract

The present invention relates to tetrazole substituted ethylsulfone/sulfoximine-pyridine derivatives of formula (I), (Ia) or (Ib) wherein the variables are as defined in the description and/or in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in/on animals as well as as crop protection agents.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A01N 43/713 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with four or more nitrogen atoms as the only ring hetero atoms
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• A01P 7/02 - Acaricides
• A01P 7/04 - Insecticides

Abstract

The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulfoximine-pyridine derivatives of formulae (I), (la) or (lb) wherein the variables are as defined in the description and/or in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in/on animals as well as as crop protection agents.

IPC Classes  ?

• C07D 213/61 - Halogen atoms or nitro radicals
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/58 - 1,2-DiazinesHydrogenated 1,2-diazines
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01N 43/82 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with three hetero atoms
• C07D 213/70 - Sulfur atoms
• C07D 213/71 - Sulfur atoms to which a second hetero atom is attached
• C07D 213/79 - AcidsEsters
• C07D 237/12 - Halogen atoms or nitro radicals
• C07D 239/30 - Halogen atoms or nitro radicals
• C07D 253/07 - 1,2,4-Triazines having three double bonds between ring members or between ring members and non-ring members with hetero atoms, or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 491/056 - Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
• C07D 498/04 - Ortho-condensed systems
• C07D 513/04 - Ortho-condensed systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems

Abstract

The present invention relates to N-oxide compounds of formula (I) or formula (Ia) or formula (Ib) wherein the variables are as defined in the description and/or in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in/on animals as well as as crop protection agents.

IPC Classes  ?

• C07D 237/26 - Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
• C07D 221/02 - Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups condensed with carbocyclic rings or ring systems
• C07D 271/06 - 1,2,4-OxadiazolesHydrogenated 1,2,4-oxadiazoles
• A01N 43/40 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
• A01N 43/58 - 1,2-DiazinesHydrogenated 1,2-diazines
• A01N 43/80 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
• A01N 43/82 - Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms, as ring hetero atoms five-membered rings with three hetero atoms
• A61P 33/14 - Ectoparasiticides, e.g. scabicides
• A61K 31/5025 - PyridazinesHydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
• A61K 31/438 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring being spiro-condensed with carbocyclic or heterocyclic ring systems

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of hypertension in a non-human mammal, preferably a carnivore, in particular a cat or a dog.

IPC Classes  ?

• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 9/12 - Antihypertensives

Goods & Services

veterinary vaccines

Goods & Services

veterinary vaccines

Abstract

This invention provides for compounds of the formula: This invention provides for compounds of the formula: wherein the variables are defined herein, or salt thereof, compositions comprising these compounds, and methods for the treatment, control and/or prevention of a parasitic infestation and/or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

IPC Classes  ?

• C07D 487/04 - Ortho-condensed systems
• C07D 491/052 - Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
• C07D 513/04 - Ortho-condensed systems

Abstract

Recombinant viral vectors and compositions that include them for use as vehicles to induce an immunological response. Multivalent viral vectors may be used in compositions or vaccines containing one or more recombinant viral vectors for protection against a variety of pathogens. Formation of these viral vectors may include insertion and expression of foreign genes to protect against a variety of pathogens. Further provided are methods of making and using the recombinant viral vectors, as well as immunogenic compositions that include the vectors and/or antigens. In particular, immunogenic compositions may include recombinant viral vectors such as vHVT509, vHVT522, and/or vHVT523.

IPC Classes  ?

• A61K 39/295 - Polyvalent viral antigensMixtures of viral and bacterial antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61K 39/145 - Orthomyxoviridae, e.g. influenza virus
• A61K 39/17 - Newcastle disease virus
• A61K 39/255 - Marek's disease virus
• A61P 31/14 - Antivirals for RNA viruses
• A61P 31/16 - Antivirals for RNA viruses for influenza or rhinoviruses
• A61P 31/22 - Antivirals for DNA viruses for herpes viruses
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 15/86 - Viral vectors

Abstract

A method and system for measuring a liquid level within a cold storage container and/or determining its cooling capacity based on the liquid level includes a sensor column. The sensor column has a plurality of resistive temperature detectors (RTDs) positioned along its length. A central controller is coupled to the plurality of RTDs. A cold storage container receives the sensor column, wherein the central controller may determine a liquid level of a cryogenic liquid held within the cold storage container using the RTDs. And based on the liquid level determined, the central controller determines a remaining cooling capacity of the cold storage container as the cryogenic liquid evaporates / changes phase over time. The central controller may also detect other conditions of the container, such as, but not limited to, a tilt position, an opened state, and/or presence of the container on a moving vehicle.

IPC Classes  ?

• G01F 23/24 - Indicating or measuring liquid level or level of fluent solid material, e.g. indicating in terms of volume or indicating by means of an alarm by measuring physical variables, other than linear dimensions, pressure or weight, dependent on the level to be measured, e.g. by difference of heat transfer of steam or water by measuring variations of resistance of resistors due to contact with conductor fluid
• A01N 1/02 - Preservation of living parts
• F17C 13/02 - Special adaptations of indicating, measuring, or monitoring equipment

Goods & Services

Scientific research in the field of veterinary medicine; providing medical and scientific research information in the field of veterinary pharmaceuticals

Goods & Services

Scientific research in the field of veterinary medicine; providing medical and scientific research information in the field of veterinary pharmaceuticals..

Goods & Services

Veterinary preparations.

Abstract

The invention relates to novel solid dispersions comprising amorphous pimobendan and one or more stabilizing polymers as well as processes of manufacturing thereof and corresponding pharmaceutical compositions.

IPC Classes  ?

• A61K 9/16 - AgglomeratesGranulatesMicrobeadlets
• A61K 9/14 - Particulate form, e.g. powders
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings

Abstract

The invention relates to novel solid dispersions comprising amorphous pimobendan and one or more stabilizing polymers as well as processes of manufacturing thereof and corresponding pharmaceutical compositions.

IPC Classes  ?

• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 9/20 - Pills, lozenges or tablets

Goods & Services

Veterinary preparations.

Abstract

Streptococcus infections in pigs. The invention provides a ΔFolT mutant of a bacterium having reduced capacity to transport folate, wherein said capacity has been reduced by functionally deleting folate transporter (FolT) function. The invention also provides a method to reduce virulence of a bacterium comprising reducing the capacity of said bacterium to transport folate.

IPC Classes  ?

• A61K 39/02 - Bacterial antigens
• A61K 39/09 - Streptococcus
• C07K 14/315 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

An administration packaging for a pharmaceutical product as well as an apparatus and a method for producing and filling such administration packaging in which a predetermined breaking zone for opening the administration packaging by breaking is generated by thermoforming. For this purpose, the apparatus has a molding tool with a forming device for forming the predetermined breaking zone. Alternatively, or in addition, the predetermined breaking zone may form a cross-section reduction or nozzle of an administration channel of the administration packaging. Alternatively, or in addition, the predetermined breaking zone may only extend over the administration channel, but not over a rim of the administration packaging. Alternatively, or in addition, the predetermined breaking zone may be formed as a kink.

IPC Classes  ?

• B29C 51/08 - Deep-drawing or matched-mould forming, i.e. using mechanical means only
• B29C 51/10 - Forming by pressure difference, e.g. vacuum
• B29C 51/26 - Component parts, details or accessoriesAuxiliary operations
• B65D 75/58 - Opening or contents-removing devices added or incorporated during package manufacture

Abstract

An administration packaging (1A, 1) for a pharmaceutical product (2) is proposed as well as an apparatus and a method for producing and filling such administration packaging (1A, 1). A predetermined breaking zone (10, 9) for opening the administration packaging (1A, 1) by breaking the breaking zone (10, 9) is generated by thermoforming. For this purpose, the apparatus comprises a molding tool (102A, 102) with a forming device for forming the predetermined breaking zone (10, 9). Alternatively or in addition, the predetermined breaking zone (10, 9) may form a cross-section reduction or nozzle (19) of an administration channel (7A, 7) of the administration packaging (1A, 1).

IPC Classes  ?

• B29C 51/08 - Deep-drawing or matched-mould forming, i.e. using mechanical means only
• B29C 51/26 - Component parts, details or accessoriesAuxiliary operations
• B29C 51/30 - Moulds
• B29C 51/42 - Heating or cooling
• B29C 65/14 - Joining of preformed partsApparatus therefor by heating, with or without pressure using wave energy or particle radiation
• B29C 65/72 - Joining of preformed partsApparatus therefor by combined operations, e.g. welding and stitching
• B29C 65/00 - Joining of preformed partsApparatus therefor
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 9/04 - Enclosing successive articles, or quantities of material, between opposed webs one or both webs being formed with pockets for the reception of the articles, or of the quantities of material
• B65B 51/14 - Applying or generating heat or pressure or combinations thereof by reciprocating or oscillating members
• B65D 1/09 - Ampoules
• B65D 75/52 - Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers Details
• B65D 75/58 - Opening or contents-removing devices added or incorporated during package manufacture
• B29C 51/10 - Forming by pressure difference, e.g. vacuum
• B29C 51/14 - Shaping by thermoforming, e.g. shaping sheets in matched moulds or by deep-drawingApparatus therefor using multilayered preforms or sheets
• B29C 51/44 - Removing or ejecting moulded articles
• B29C 65/18 - Joining of preformed partsApparatus therefor by heating, with or without pressure using heated tool
• B29L 31/00 - Other particular articles
• B65B 3/02 - Machines characterised by the incorporation of means for making the containers or receptacles

Abstract

The invention relates to an administration packaging and method for its production. The administration packaging comprises a bottom part and a cover which are obtained from multi-layer films.

IPC Classes  ?

• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins
• B32B 3/30 - Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a particular shape of the outline of the cross-section of a continuous layerLayered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shapeLayered products comprising a layer having particular features of form characterised by a layer with cavities or internal voids characterised by a layer formed with recesses or projections, e.g. grooved, ribbed
• B32B 7/05 - Interconnection of layers the layers not being connected over the whole surface, e.g. discontinuous connection or patterned connection
• B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• B32B 27/36 - Layered products essentially comprising synthetic resin comprising polyesters
• B65D 65/40 - Applications of laminates for particular packaging purposes
• A61J 1/06 - Ampoules or cartridges
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor

Abstract

The present disclosure relates to an apparatus (10) for classifying at least one audio signal (20). The apparatus (10) comprises an input interface (12) configured to receive input information (22) of the audio signal (20), a trained first machine-learning-based classifier (16) configured to map the input information (22) to one of a first and a second class of audio signals (24; 26); a trained second machine-learning-based classifier (18) configured to, if the audio signal (20) belongs to the first class of audio signals (24), map the input information (22) of the audio signal belonging to the first class of audio signals (24) to one of a plurality of third classes (28) of audio signals, and an output interface configured to output information on which classes the audio signal (20) belongs to.

IPC Classes  ?

• A61B 7/00 - Instruments for auscultation
• G06N 3/08 - Learning methods
• G10L 25/30 - Speech or voice analysis techniques not restricted to a single one of groups characterised by the analysis technique using neural networks
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems

Abstract

An administration packaging and method for its production. The administration packaging having a bottom part and a cover which are formed of multi-layer films.

IPC Classes  ?

• A61J 1/06 - Ampoules or cartridges
• A61J 1/14 - Containers specially adapted for medical or pharmaceutical purposes DetailsAccessories therefor
• B32B 7/02 - Physical, chemical or physicochemical properties
• B32B 27/08 - Layered products essentially comprising synthetic resin as the main or only constituent of a layer next to another layer of a specific substance of synthetic resin of a different kind
• B32B 27/30 - Layered products essentially comprising synthetic resin comprising vinyl resinLayered products essentially comprising synthetic resin comprising acrylic resin
• B32B 27/32 - Layered products essentially comprising synthetic resin comprising polyolefins
• B65B 3/00 - Packaging plastic material, semiliquids, liquids or mixed solids and liquids, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans or jars
• B65B 3/02 - Machines characterised by the incorporation of means for making the containers or receptacles
• B65D 75/32 - Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
• B65D 75/58 - Opening or contents-removing devices added or incorporated during package manufacture

Goods & Services

interactive databases containing information in the field of parasites in pets; computer applications and internet-based applications in the field of parasites in pets; software and software applications for mobile devices in the field of parasites in pets. providing medical and scientific research information in the field of parasites in pets. veterinary services provided via mobile application software in the field of parasites in pets.

Goods & Services

Veterinary preparations, for the prevention and the treatment of metabolic diseases; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damage and injuries; veterinary preparations for the prevention and the treatment of hormonal diseases and disorders; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the prevention and the treatment of parasites; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; veterinary vaccines; sedatives for animals; veterinary preparations, namely, stem cells for veterinary use

Goods & Services

(1) Veterinary preparations, for the prevention and the treatment of metabolic diseases; veterinary preparations for the prevention and the treatment of cardiovascular diseases; veterinary preparations for the prevention and the treatment of neurological diseases and disorders; veterinary preparations for the prevention and the treatment of musculoskeletal diseases and disorders; veterinary preparations for the prevention and treatment of tendon and muscle damage and injuries; veterinary preparations for the prevention and the treatment of hormonal diseases and disorders; veterinary preparations against bacterial infections, namely, antibiotics, anti-infectives; veterinary preparations for the prevention and the treatment of respiratory diseases; veterinary preparations for the prevention and the treatment of parasites; veterinary preparations for the treatment of inflammatory diseases; veterinary preparations for udder care; veterinary vaccines; sedatives for animals; veterinary preparations, namely, stem cells for veterinary use.

Abstract

The present invention is directed to the use of one or more SGLT-2 inhibitors or pharmaceutically acceptable forms thereof for the prophylaxis and/or treatment of one or more cardiac diseases in feline animals.

IPC Classes  ?

• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 47/54 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additivesTargeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
• A61P 9/04 - Inotropic agents, i.e. stimulants of cardiac contractionDrugs for heart failure
• A61K 31/138 - Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/401 - ProlineDerivatives thereof, e.g. captopril
• A61K 31/4184 - 1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
• A61K 31/4422 - 1,4-Dihydropyridines, e.g. nifedipine, nicardipine
• A61K 31/501 - PyridazinesHydrogenated pyridazines not condensed and containing further heterocyclic rings
• A61K 31/554 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
• A61K 31/585 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
• A61K 31/616 - Salicylic acidDerivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/727 - HeparinHeparan

Abstract

The current invention relates to mesenchymal stem cells (MSCs) or a pharmaceutical composition comprising an effective amount of MSCs for use in the treatment of insect-bite hypersensitivity (IBH) in equines.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 37/08 - Antiallergic agents

Abstract

The disclosure relates to the field of medicine, in particular to the field of veterinary medicine. The disclosure relates to a pharmaceutical (medicament) formulation of glucocorticoids, especially ciclesonide or a pharmaceutically acceptable derivative thereof.

IPC Classes  ?

• A61K 47/02 - Inorganic compounds
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/08 - Solutions
• A61P 11/00 - Drugs for disorders of the respiratory system
• A61K 31/58 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers

Goods & Services

Education and providing of training in the veterinary field related to diabetes in pets; preparation and running of congresses and seminars in the veterinary field for educational purposes. Providing of medical and scientific research information in the veterinary field related to diabetes in pets.

Goods & Services

Veterinary vaccines for avians.

IPC Classes  ?

• A23K 20/111 - Aromatic compounds
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom
• A23K 20/132 - Heterocyclic compounds containing only one nitrogen as hetero atom
• A23K 50/10 - Feeding-stuffs specially adapted for particular animals for ruminants
• A23K 50/20 - Feeding-stuffs specially adapted for particular animals for horses
• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23K 50/48 - Moist feed
• A61K 9/08 - Solutions
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 38/12 - Cyclic peptides
• A61K 47/02 - Inorganic compounds
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof

Abstract

The invention relates to novel aqueous pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more solubilizing agents as well as corresponding processes of manufacturing such aqueous pharmaceutical compositions and their medical uses.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 31/7004 - Monosaccharides having only carbon, hydrogen and oxygen atoms
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/02 - Inorganic compounds
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/46 - Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin

Abstract

The invention relates to novel aqueous pharmaceutical compositions comprising at least one SGLT-2 inhibitor and one or more solubilizing agents as well as corresponding processes of manufacturing such aqueous pharmaceutical compositions and their medical uses.

IPC Classes  ?

• A61K 9/08 - Solutions
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 47/02 - Inorganic compounds
• A61K 47/06 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
• A61K 47/10 - AlcoholsPhenolsSalts thereof, e.g. glycerolPolyethylene glycols [PEG]PoloxamersPEG/POE alkyl ethers
• A61K 47/12 - Carboxylic acidsSalts or anhydrides thereof
• A61K 47/14 - Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
• A61K 47/20 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
• A61K 47/22 - Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
• A61K 47/26 - Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharidesDerivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
• A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
• A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 47/38 - CelluloseDerivatives thereof
• A61K 31/70 - CarbohydratesSugarsDerivatives thereof
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings
• A61K 38/12 - Cyclic peptides
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom
• A23K 20/111 - Aromatic compounds
• A23K 20/132 - Heterocyclic compounds containing only one nitrogen as hetero atom
• A23K 50/10 - Feeding-stuffs specially adapted for particular animals for ruminants
• A23K 50/20 - Feeding-stuffs specially adapted for particular animals for horses
• A23K 50/40 - Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
• A23K 50/48 - Moist feed
• A61P 1/00 - Drugs for disorders of the alimentary tract or the digestive system

Abstract

The invention relates to a liquid applicator, for administering liquids, including vaccines, to animals. In particular, the applicator is useful for delivering liquids to mouths of animals.

IPC Classes  ?

• A61D 1/02 - Trocars or cannulas for teatsVaccination appliances
• A61J 1/06 - Ampoules or cartridges
• A61D 7/00 - Devices or methods for introducing solid, liquid, or gaseous remedies or other materials into or onto the bodies of animals
• A61J 1/20 - Arrangements for transferring fluids, e.g. from vial to syringe
• A61K 39/02 - Bacterial antigens
• A61M 3/00 - Medical syringes, e.g. enemataIrrigators

Goods & Services

(1) Education and providing of training in the veterinary field related to diabetes in pets; preparation and running of congresses and seminars in the veterinary field for educational purposes. (2) Providing of medical and scientific research information in the veterinary field related to diabetes in pets.

Goods & Services

Providing educational courses and training in the veterinary field related to diabetes in pets; preparation and running of congresses and seminars in the veterinary field for educational purposes Providing of medical and scientific research information in the veterinary field related to diabetes in pets

Abstract

The present invention is directed to the use of at least one SGLT-2 inhibitor in a non-human mammal, preferably ruminant, preferably for drying-off of a non-human mammal, preferably ruminant, as well as corresponding methods, such as improving and/or facilitating the drying-off of a non-human mammal, preferably ruminant, comprising administering to such non-human mammal, preferably ruminant, at least one SGLT-2 inhibitor.

IPC Classes  ?

• A61K 31/7048 - Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin
• A23K 20/24 - Compounds of alkaline earth metals, e.g. magnesium
• A23K 20/121 - Heterocyclic compounds containing oxygen or sulfur as hetero atom
• A61P 15/14 - Drugs for genital or sexual disordersContraceptives for lactation disorders, e.g. galactorrhoea
• A61K 31/351 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/7056 - Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
• A61K 31/382 - Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
• A61K 31/7028 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
• A61K 31/7034 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
• A61K 31/7042 - Compounds having saccharide radicals and heterocyclic rings

Abstract

The present invention relates i.a. to a recombinant avian coronavirus spike protein or fragment thereof comprising a mutation at amino acid position 267 to Cysteine. Further, the present invention relates to an immunogenic composition comprising an avian coronavirus with such spike protein.

IPC Classes  ?

• A61K 39/215 - Coronaviridae, e.g. avian infectious bronchitis virus
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61K 39/12 - Viral antigens
• A61P 31/14 - Antivirals for RNA viruses
• A61P 37/04 - Immunostimulants
• C07K 14/005 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from viruses
• C12N 7/00 - Viruses, e.g. bacteriophagesCompositions thereofPreparation or purification thereof
• C12N 15/85 - Vectors or expression systems specially adapted for eukaryotic hosts for animal cells

Goods & Services

Antiparasitic preparations for veterinary purposes.

Goods & Services

Antiparasitic preparations for veterinary purposes.

IPC Classes  ?

• A61K 39/12 - Viral antigens

Abstract

The present invention relates to immunogenic compositions comprising recombinantly constructed polypeptides useful for preparing vaccines, in particular for reducing one or more clinical signs caused by a rotavirus infection. More particular, the present invention is directed to an immunogenic composition containing (i) a fusion protein comprising in N- to C-terminal direction (A) an immunogenic fragment of a rotavirus VP8 protein and (B) an immunoglobulin Fc fragment such as, for example, an IgG Fc fragment, and (ii) an immunogenic substance, different from said fusion protein, wherein said immunogenic composition is usable in a method of reducing one or more clinical signs, mortality or fecal shedding caused by a rotavirus infection in swine.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A method and system provide a folded mailer system which can house / enclose a container which houses a liquid. The folded mailer system meets the requirements /standards as set forth by the USPS for first-class machinable mail. While the folded mailer system meets the USPS requirements / standards for first-class machinable mail, the folded mailer system may also meet the requirements / standards for machinable mail in other jurisdictions outside of the United States. The mailer system may include a container capable of holding a liquid and a structure for holding the container when the container is shipped. The structure may have at least two sections which are folded on to each other when the container is shipped. The container and structure may be machinable within an automated mailing system that is run by the USPS.

IPC Classes  ?

• B65D 75/22 - Articles or materials wholly enclosed in single sheets or wrapper blanks in sheets or blanks doubled around contents and having their opposed free margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding the sheet or blank being recessed to accommodate contents
• B65D 83/00 - Containers or packages with special means for dispensing contents

Abstract

The present invention relates to the use of an immunogenic composition that comprises a porcine circovirus type 3 (PCV3) antigen for treatment of several clinical manifestations (diseases). Preferably, the clinical manifestations are associated with a PCV3 infection.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• A61P 37/04 - Immunostimulants
• A61P 31/20 - Antivirals for DNA viruses
• A61K 39/23 - Parvoviridae, e.g. feline panleukopenia virus
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Goods & Services

Antiparasitic preparations for veterinary purposes

Goods & Services

Antiparasitic preparations for veterinary purposes

Goods & Services

Antiparasitic preparations for veterinary purposes

Goods & Services

Veterinary preparations; vaccine for veterinary use.

Goods & Services

Veterinary preparations; vaccine for veterinary use.

Abstract

The present invention relates to African swine fever virus (ASFV) peptides and/or polypeptides as well as immunogenic fragments thereof, corresponding encoding AFSV oligonucleotides and/or polynucleotides as well as immunogenic fragments thereof, immunogenic compositions, vaccines and uses thereof.

IPC Classes  ?

• A61K 39/12 - Viral antigens
• C12N 15/74 - Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
• C12N 15/86 - Viral vectors
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

A folded mailer system (101) comprising a container (105) which houses a liquid and a structure (103) having at least two sections (102a, 104a) which are folded on to each other when the container is shipped. The container (105) and structure (103) are machinable within an automated mailing system.

IPC Classes  ?

• B65D 27/00 - Envelopes or like essentially-rectangular flexible containers for postal or other purposes having no structural provision for thickness of contents
• B65D 75/38 - Articles or materials enclosed in two or more wrappers disposed one inside the other

Goods & Services

(1) Vaccine for veterinary use.

Goods & Services

Vaccine for veterinary use

Goods & Services

vaccine for veterinary use

Goods & Services

(1) Vaccine for veterinary use.

Abstract

The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I) The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I) The present invention relates to cyclopropyl-(hetero)aryl substituted ethylsulphonyl-pyridine derivatives of formula (I) wherein the variables are as defined in the description and in the claims, which can be used as antiparasitic agents for the treatment, prevention and/or control of parasitic infections and/or infestations in animals.

IPC Classes  ?

• C07D 471/04 - Ortho-condensed systems
• C07D 487/04 - Ortho-condensed systems
• C07D 413/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 498/04 - Ortho-condensed systems
• C07D 401/04 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 513/04 - Ortho-condensed systems
• C07D 417/04 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 401/14 - Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

This invention provides for compounds of the formula: This invention provides for compounds of the formula: This invention provides for compounds of the formula: wherein the variables are defined herein, or a stereoisomer, tautomer, N-oxide, hydrate, solvate, or salt thereof, compositions comprising these compounds, and method for the treatment, control or prevention of a parasitic infestation or infection in an animal in need thereof by administering an effective amount of these compounds to said animal.

IPC Classes  ?

• C07D 495/04 - Ortho-condensed systems
• C07D 413/14 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
• C07D 409/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• C07D 407/12 - Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group containing two hetero rings linked by a chain containing hetero atoms as chain links
• A61P 33/10 - Anthelmintics
• C07D 307/85 - Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 2
• C07D 519/00 - Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups or
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Abstract

A method for analyzing an acoustic signal having a time period and having a plurality of repeated audio patterns, has the following steps: receiving an audio signal having the acoustic signal; determining the audio patterns repeated within the acoustic signal; determining a window length for a plurality of windows, wherein the window length divides the time period of the acoustic signal into the plurality of windows; and windowing the acoustic signal to obtain the plurality of windows.

IPC Classes  ?

• A61B 5/0255 - Recording instruments specially adapted therefor
• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 7/04 - Electric stethoscopes